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Summary The variation in survival of women with clinically similar breast cancers may lead to difficulty in
clinical management so it is important to recognise factors which indicate the prognosis. Immunoperoxidase
staining patterns of primary breast tumours using monoclonal antibody NCRC- 11 have been shown to relate
to overall survival (Ellis et al., 1985) but the results have not been reproducible in other centres. In this study
paraffin sections of483 primary breast cancers were stained with NCRC-11 and 3E1.2 using an immunoperox-
idase system. The tumour staining patterns were compared with overall survival using life tables and tested for
relative prognostic significance by Cox's multivariate analysis. NCRC- I related to survival in all 483 cases (X2
5.8, P = 0.02) but both antibodies achieved maximum prognostic significance in lymph node negative patients
(X2 9.4, P<0.002 and X2 10.7, P<0.001) in whom no other factor was more significant. Immunoperoxidase
staining patterns produced by monoclonal antibodies NCRC-11 and 3E1.2 are important prognostic factors in
breast cancer.
The survival of women with clinically similar breast tumours
may vary widely. In consequence the choice of treatment, the
counselling of the patient and the interpretation of the results
of clinical trials increasingly rely on laboratory tests of
tumour biology in addition to clinical signs. Of all prognostic
factors the histological diagnosis of lymph node metastases is
the factor which relates most strongly to a poor prognosis
and additionally the number and level of involved nodes
affects survival (Fisher et al., 1983). Factors relating to histo-
logical differentiation and hormone receptor status have also
been found to have prognostic significance (Elston, 1984;
Bryan et al., 1986) but this in the former is observer depen-
dent (Gilchrist & Kalish, 1985) and in the latter probably
only applies in lymph node positive cases (Williams et al.,
1987). There is therefore a need to discover other prognostic
factors which will help in patient management and in under-
standing more of the biology of breast cancer. This paper
describes the investigation of the prognostic value of mono-
clonal antibodies (MoAbs) NCRC- 11 and 3E1.2 in 483
women with primary breast cancer. Both of these MoAbs are
of the anti-Epithelial Membrane Antigen (EMA) type and
their characterisations and clinical uses have been described
elsewhere (Ellis et al., 1984, 1985; Stacker et al., 1985, 1988,
1989). The synthesis of EMA by mammary acini and ducts is
thought to be a specialised function and therefore tumours
which contain EMA in abundance may be better different-
iated and hence have a better prognosis than those in which
it is less plentiful. In two studies using NCRC-1 and an
immunoperoxidase method a relationship was demonstrated
between well stained tumours and a favourable prognosis
(Ellis et al., 1985, 1987). In a smaller study this relationship
could not be confirmed (Angus et al., 1986) and no such
study has been undertaken for 3E1.2. By using a large series
of unselected patients followed-up for between 5 and 10
years, this study attempts to clarify the prognostic worth of
both NCRC-11 and 3E1.2.
Patients and methods
Clinico-pathological data
Since 1976 the steroid receptor laboratory in the Department
of Surgery at St Vincent's Hospital has assessed over 6,000
breast tumours. During this time it has been the policy of
surgeons in the state of Victoria to submit specimens of all
primary breast cancers for analysis. The patients for study
were selected in sequence from the departmental records if
the tumour was a primary breast cancer and the referring
pathologist was prepared to release the appropriate paraffin
block. No other selection criteria were applied. Four hundred
and eighty-three patients were available for study with
follow-up ranging from 5 to 10 years or to death. Treatment
was not standardised though 87% received Patey mastec-
tomy, 8% simple mastectomy and 5% lumpectomy. No data
were available regarding treatment by radiotherapy or
chemotherapy but in the time when these patients were
treated there was no evidence to suggest that the parameters
studied here would influence either a patient's selection for or
response to this type of therapy. These patients represent a
random sample of women with primary breast cancer treated
in the state of Victoria between January 1976 and December
1981.
All patients had oestrogen receptor assays, 388 had proges-
terone receptor assays and 233 had androgen receptor assays.
In 246 cases histological grade was assessed by one of us
(RR) according to the criteria of Bloom and Richardson
(1957) and in all cases histological type was known. Tumour
size was known in 451 cases, and the number of involved
nodes in 425 cases.
Follow-up information was obtained from the Common-
wealth of Australia Electoral Register, the Anti-Cancer
Council of Victoria and the referring surgeons and general
practitioners.
Technical methods
All archival material had been treated by formalin fixation
alone with the exception of specimens from one laboratory
which, in addition, used mercuric chloride secondary fixation.
New paraffin sections were cut from the blocks, three were
stained by a peroxidase anti-peroxidase (PAP) method (Ellis
et al., 1985) with NCRC-lI1, 3E1.2 and a negative control
MoAb. A fourth section was stained by haematoxylin and
eosin for assessment of histological grade. Prior to the pre-
sent study an extensive assessment was made of other types
of IP staining methods and the effect of many different
regimes for tissue fixation. In breast cancer sections, with the
MoAbs studied, the PAP method gave consistently repro-
ducible results irrespective of fixation regime.
Assessment of MoAb stained sections consisted of light
microscopic estimation of the percentage of carcinoma cells
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stained irrespective of the part of the cell stained or the type
of tumour. The percentage was then expressed as a score
such that 0-25% scored 1, 26-50% scored 2, 51-75%
scored 3 and tumours with greater than 75% of carcinoma
cells staining scored 4. An average score is given when a
tumour shows heterogeneity of staining. The scoring method
has already been thoroughly documented (Muir et al., 1987)
and is not elaborated on here. It is easy to learn and has a
high degree of observer reproducibility and interobserver
correlation.
A computer file was compiled of the data for each patient
and the file was analysed using the BMDP statistical software
package (Dixon, 1983). MoAb staining was compared with
other tumour data using chi-squared tests and Pearson's
corelation coefficient then with survival using life table analy-
sis. The prognostic value of staining score relative to that of
other clinico-pathological data was assessed by Cox's multi-
variate analysis. Survival analyses were performed for all
cases and separately for lymph node negative and lymph
node positive cases.
Results
Sixty-three per cent of tumours had identical staining scores
with both MoAbs and in a further 27% the difference in
score was only one unit. The scatterplot (Figure 1) shows
that where staining scores were not equal, that NCRC-l1
tends to stain more carcinoma cells then 3E1.2.
Staining score with both MoAbs was strongly related to
oestrogen receptor status, progesterone receptor status and
histological grade and weakly associated with age at the time
of diagnosis (Table I). Staining did not relate to histological
type, androgen receptor status, lymph node involvement or
tumour size.
NCRC-l1 staining score related to prognosis in all 483
cases, x2 5.8; P<0.02 (Figure 2) but the prognostic value is
clearer when staining scores 1 and 2, 3 and 4, are amalga-
mated (Figure 3). This is consistent with the findings of Ellis
et al. (1987).
In all 483 patients 3E1.2 staining did not have prognostic
value though it approached statistical significance when stain-
ing scores 1 and 2, 3 and 4, were amalgamated, x2 3.4,
P=0.06.
In the 223 lymph node negative patients both NCRC-l
and 3E1.2 staining scores related to survival (Figures 4, 5)
with respective X2 value 9.4, P<0.002, and 10.7, P<0.001.
In 202 lymph node positive patients staining score with
neither of the MoAbs related to survival, x2 2.38 and 0.28. In
this group the number of positive nodes (X2 5.5), tumour size
(X2 7.5), oestrogen receptor status (X2 8.4) and progesterone
receptor status (X2 10.4) related to survival.
The Cox Analysis for all 483 patients indicated that the
following factors were associated with prognosis: lymph
node status, number of involved nodes, tumour size, oestro-
gen receptor status, progesterone receptor status, age and
NCRC-l I staining score. The factors found to have indepen-
dent prognostic significance and a measure of their discrim-
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Figure 1 Scatterplot showing comparative staining scores with 2
MoAbs in 483 cases.
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Figure 2 Life table showing survival according to NCRC-1 1
staining score in 483 cases.
ination are shown in Table II. It is noteworthy that, once the
prognostic value of progesterone receptor has been accounted
for, oestrogen receptor status no longer had discriminatory
power.
In node negative patients staining score with the 2 MoAbs
Table I Statistical relationships between MoAb staining scores and other clinico-pathological
data
ER PR AR Histological Node Tumour
status status status grade Age status size
X234.3 X2 22.9 X23.8 x2 31.3 R=0.15 X2 7.1
NCRC-1 1 3 d.f. 3 d.f. 3 d.f. 6 d.f. 3 d.f. R = 0.07
* * NS * ** NS NS
X228.8 X2 24.9 X2 3.7 x227.4 R=0.14 X2 3.1
3E1.2 3 d.f. 3 d.f. 3 d.f. 6 d.f. 3 d.f. R = 0.07
* * NS * ** NS NS
*P<0.0001; **P<0.001; NS, notstatisticallysignificant; d.f.,degreesoffreedom; X2valueswere
obtained from contingency tables, R = Pearson's correlation coefficient.
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Figure 3 Life table showing survival in 483 cases with MoAb
NCRC-l . Staining scores 1 and 2, 3 and 4 have been combined.
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Figure 4 Life table showing survival in 223 lymph node negative
cases with MoAb NCRC- 1. Staining scores I and 2, 3 and 4
have been combined.
and progesterone receptor status related to survival. The Cox
analysis showed that 3E1.2 staining score had the greatest
discrimination in this group and neither of the other factors
was sustained as having independent prognostic significance.
Discussion
The results of this study confirm that NCRC-l1 staining
score is a powerful prognostic factor in patients with breast
cancer. It is likely that the large number of patients studied
and the long minimum follow-up have revealed a survival
difference which has not come to light in smaller studies of
NCRC-11 which have had shorter follow-up periods.
New discoveries are the relationship of 3E1.2 staining
score to survival and, that for both MoAbs, the prognostic
value is dependent on lymph node status. Both MoAbs had
their maximum prognostic significance in lymph node nega-
tive patients but neither had prognostic value in node
positive patients. It is therefore likely that the relationships
demonstrated between NCRC-l1, 3E1.2 and survival in all
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Figure 5 Life table showing survival in 223 lymph node negative
cases with MoAb 3E1.2. Staining scores 1 and 2, 3 and 4 have
been combined.
TableII Orderinwhichvariables wereremoved from theCoxanalysis
for all 483 patients and the global chi-squared value for the total
prognostic information
Variable Chi-squared value
Nodal status 26.8
PR status 17.5
Size(> or <5cms) 16.5
NCRC-11 5.8
Nodes(l-3or>3) 4.1
Global chi-squared 86.5
483 cases are due to the influence of node negative patients
rather than an ability of the MoAbs to discriminate between
unselected cases. The effect of lymph node involvement on
the discriminatory value of other prognostic factors has also
been demonstrated for oestrogen receptor status (Williams,
1987) and epidermal growth factor status (Nicholson, 1989).
In the present instance it is likely that the poor prognosis
afforded by lymph node metastases outweighs any benefit
from favourable MoAb staining. In node negative cases thle
degree of staining may relate to the predisposition of the
tumour to form distant metastases or to the development of
metastases in more or less lethal sites. In node negative cases
MoAb staining score was the dominant prognostic factor.
Progesterone receptor status was the only other factor
significantly related to survival in this group but the Cox
analysis showed that this was not independent of staining
score.
MoAb staining score was not found to be a strong enough
predictor of survival to discern more than two groups of
patients, i.e. those with more or less than 50% of carcinoma
cells stained. Of all the factors investigated only the extent of
lymph node metastases possessed this property, i.e. groups
'O' nodes involved, '1-3' nodes involved and '4 or more'
nodes involved. No relationship was demonstrated between
histological grade and survival though favourable MoAb
staining correlated with better histologically differentiated
tumours.
It is concluded that immunoperoxidase staining score with
NCRC-11 and 3E1.2 is a powerful prognostic factor in
patients with breast cancer. This may have clinical signifi-
cance in indicating which lymph node negative patients are at
high risk and who may be considered for adjuvant treatment.
It is suggested that investigators of other prognostic factors
should stratify their results according to the lymph node
status of their patients.
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